Introduction
Activation of T lymphocytes is initiated by the interaction of the IL-2 enhancer (6-8). Stimulation of the TCR results in rapid activation of the Ras-Raf-mitogen-activated kinase or the TCR-CD3 and its cognate antigen. Stimulation of TCR alone is, however, insufficient to induce proliferation and microtubule-associated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK)-ERK kinase cassynthesis of the ultimate mitogen, IL-2, rather causing a state of clonal anergy (reviewed in 1,2). In combination with cade (9). However, activation of the 'classical' MAPK cascade appears to be a necessary but not a sufficient signaling additional signals-triggered by either accessory molecules or cytokines-T cells become optimally activated (3) (4) (5) .
pathway for induction of lymphokine, particularly IL-2 synthesis in stimulated T lymphocytes (10-13). This is consistent Besides the requirement for 'accessory signals' via co-receptors, like CD2, CD4/8, CD5 and CD28, the cytokine IL-1 has with the finding that T cell activation requires co-stimulatory signals in addition to those activated via the TCR-CD3 been shown to synergize with mitogenic lectins or anti-TCR antibodies to induce IL-2 synthesis and cellular proliferation complex (14). How these distinct stimuli act synergistically to cause T cell activation has not been fully elucidated. (reviewed in 6). Whether the IL-1 signal plays an enhancing or obligatory role in T cell activation is discussed controversially.
Besides the best characterized 'classical' MAPK subfamily, including ERK-1 and ERK-2, two additional groups of MAPK More importantly, the molecular mechanisms underlying the co-stimulatory activity of IL-1 still remain unclear.
have been identified recently, i.e. Jun-N-terminal kinases (JNK), also termed stress-activated kinases (SAPK), and p38 Both the TCR and IL-1 regulate the expression of the IL-2 gene at the transcriptional level. Several signal transduction MAPK (reviewed in 14).
While it is well established that the 'classical' MAPK pathway cascades have been implied to be involved in the control of Correspondence to: M. Szamel Transmitting editor: M. Reth Received 11 December 1998, accepted 5 August 1999 regulates important TCR induced functions, much less is of 10 5 -10 6 cells/ml. Prior to treatment cells were serum starved for 12-14 h. known about implications of the JNK and p38 MAPK cascades in the course of T cell activation (15). The latter two groups Before activation cells were pre-treated with 50 µM PD-98059 (MEK-1 inhibitor) (21), 10 µM SB-203580 (inhibitor of of MAPK (i.e. JNK and p38 MAPK) are effectively activated by IL-1 in several non-lymphoid cells and cell lines (16) (17) (18) (19) . p38 MAPK) (22) or their combination for 90 min. Cells were then stimulated with 2.5 µg/ml anti-CD3 antibody, 2.5 ng/ml The activation and function of JNK/p38 MAPK is less well characterized in T lymphocytes.
IL-1β or their combination for the times indicated in the experiments. Activation of MAPK pathways results in phosphorylation of transcription factors, thereby transducing signals from cell Isolation of splenic lymphocytes surface receptors to the nucleus. Some transcription factors are substrates for all three groups of MAPK, whereas others Spleens from BALB/c mice (6-8 weeks old) were minced and are preferential substrates of distinct groups of protein gently smashed in a loose-fitting glass homogenizer for cell kinases, like the N-terminal activation domain c-Jun, which is release. The cell suspension was filtered through nylon wool phosphorylated by JNK/SAPK (14). Simultaneous stimulation and washed 3 times with RPMI medium. Cells were incubated of distinct MAPK cascades via two different cell surface at a density of 5ϫ10 6 /ml in RPMI 1640 containing 20% FCS, receptors might therefore amplify a signal by converging on 50 µM β-mercaptoethanol, 2 mM L-glutamine, 100 U/ml the same effector molecules (e.g. transcription factors) or penicillin and 0.1 mg/ml streptomycin in plastic flasks overelicit an enhanced cellular response if distinct effector molenight to deplete the majority of adherent cells. Before stimulacules are activated.
tion cells were washed 3 times with RPMI medium then To get insight into the molecular events being responsible incubated with 2.5 µg/ml anti-CD3 antibody, 2.5 ng/ml IL-1β for IL-1-induced co-stimulatory activity in T cells, activation of or 0. Electrophoretic mobility shift assay (EMSA) Nuclear extracts from samples of 1ϫ10 7 cells were obtained using a standard protocol (23,24). For the EMSA the following oligonucleotides were used (6): IL-2 distal nuclear factor of activated T cells (NFAT) site: GAT CGC CCA AAG AGG AAA ATT TGT TTC ATA CAG; NFκB: AAT TCA CAA AGA GGG DTT, 500 mM NaCl and 50% glycerol, pH 7.5) for 30 min at 30°C in the presence of 5-7.5 µg protein, as indicated in the experiments. Protein-DNA complexes were separated in a native polyacrylamide gel (4%) and visualized by autoradiography. gels and then blotted on a nylon membrane (Quiagen) by capillary transfer using standard procedures (24). RNA was Determination of IL-2 synthesis cross-linked by UV irradiation, the blot prehybridized in 50% Cells (1ϫ10 6 ) were preincubated with protein kinase inhibitors formamide, 5ϫSSPE, 5ϫDenhardt's, 10% dextran sulfate and (50 µM PD-98059 and 10 µM SB-203580) for 90 min. Cells 1 mg/ml salmon sperm DNA for 2 h at 42°C, and then were washed and stimulated with anti-CD3 antibodies, IL-1 hybridized for 20 h at 42°C with the IL-2-specific cDNA. The or their combination for 18 h. IL-2 concentration of the membrane was washed twice with 5ϫSSC/0.1% SDS at 42°C supernatants was determined by a specific ELISA (Genzyme for 10 min followed by incubation for 30 min in 1ϫSSC/0.1% DuoSet for murine IL-2) according to the manufacturer's SDS at 60°C. Hybridization with GAPDH was performed to instructions (Genzyme, Cambridge, MA).
standardize the signals.
The IL-2-specific cDNA used for Northern hybridization was Isolation of RNA and Northern blot analysis amplified by reverse transcription from RNA isolated from EL-4 cells. PCR was performed at an annealing temperature of RNA was prepared using the Quiagen RNeasy kit from Quiagen (Hilden, Germany). First, 15 µg of total RNA was 65°C for 40 cycles with the following primers (Pharmacia, Freiburg, Germany): primer 1: 5Ј-AAG CTC CAC TTC AAG separated by electrophoresis on 1% agarose/formaldehyde 10 7 ) were incubated with 2.5 µg/ml anti-CD3 antibody or with 2.5 ng/ml IL-1β for the times indicated. MEK-1 was immunoprecipitated with a specific antibody and its activity measured with hr-ERK-1 as substrate, as described under Methods. After separation by SDS-PAGE phosphorylated proteins were visualized by autoradiography. Results are representative for two independent experiments. (B) Cells (10 7 ) were stimulated with IL-1 or anti-CD3 for the times indicated. JNK was immunoprecipitated and subjected to an in vitro kinase assay using hr-GSTJun fusion protein as substrate according to Methods. Proteins were separated by SDS-PAGE and visualized by autoradiography. Results are representative for four independent experiments. (C) Cells (10 7 ) were incubated with 2.5 µg/ml anti-CD3 antibody or with 2.5 ng/ml IL-1β respectively for the times indicated. p38 MAPK was immunoprecipitated by a specific antibody, then subjected to an in vitro kinase assay with hr-MAPKAPK-2 (left part) or hr-ATF-2 (right part) as substrates. Phosphorylated proteins were processed to SDS-PAGE and autoradiography as described under Methods. Results are representative for two independent experiments. CTC TAC AGC G-3Ј; primer 2, 5Ј-TTG ACA GAA GGC TAT kit from Quiagen, following the manufacturer's instructions. The IL-2-specific cDNA was labeled with 30 µCi [α-32 P]dATP CCA TCT CCT C-3Ј. The product (412 bp) was separated on 1% agarose gels and eluted using the Quaquick gel extraction (Hartmann, Braunschweig, Germany) using the Randomprime DNA labeling system from Amersham (Braunschweig, Germany).
Results

EL-4 cells express functionally active TCR-CD3 complexes and type I IL-1R
As shown in Fig. 1(A) , the EL-4 cells expressed a high number of TCR as measured by staining with a PE-labeled antibody by FACScan. Figure 1(B) shows that the EL-4 subline also expressed a high number of IL-1R, as detected with a specific antibody against the type I IL-1R. Practically all cells possessed both receptors (Fig. 1C) .
To ensure that both receptors were functionally active, IL-2 synthesis was measured in activated cells. Upon stimulation with anti-CD3 antibodies the cells synthesized 300 pg/ml IL-2. Similarly, the supernatants of IL-1-stimulated cells contained 250-300 pg/ml of the cytokine. Upon combination of both stimuli IL-2 synthesis was markedly enhanced, i.e. the cells secreted 1000 pg/ml of the lymphokine. These results show that simultaneous activation via TCR and type I IL-1R resulted in a synergistic enhancement of IL-2 synthesis (see also Figs  6D and 7) .
In order to investigate whether distinct signal transduction pathways were involved in activation of IL-2 synthesis, protein kinase cascades stimulated via the TCR or IL-1R were studied in detail.
Activation of the 'classical' MAPK pathway via TCR-CD3 and IL-1 R As shown in Fig. 2(A) , stimulation with both IL-1 and anti-CD3 antibody resulted in an increase in the phosphorylation of ERK-1 as measured by an in vitro kinase assay upon immunoprecipitation of MEK-1, one of the specific upstream activators of ERK. Both anti-CD3-and IL-1-activated MEK catalyzed (Fig. 2B) . In allowed to ensure that ATF-2 phosphorylation was not due to contaminating SAP/JNK activities. As shown in Fig. 2(C) , phosphorylation of both MAPKAPK-2 and ATF-2 by p38 MAPK was markedly enhanced by IL-1 as compared to control. In lymphocytes. Upon IL-1 treatment JNK were activated between 10 and 30 min (Fig. 3A) . Activation by IL-1 also contrast, stimulation of cells with anti-CD3 antibodies did not affect p38 MAPK activity (Fig. 2C, lanes 2-4 and 9-11) .
resulted in enhanced phosphorylation and thus activation of p38 MAPK, as detected by a pp38 MAPK-specific mAb. (Fig.  Similar results were obtained in stimulated murine spleen 3B). Stimulation via TCR did not influence SAPK, i.e. JNK and that declined to control levels after 120 min. In IL-1-stimulated cells enhanced NFAT binding was detected later, i.e. between p38 MAPK in murine lymphocytes (data not shown).
Taken together, the data shown in Figs 2 and 3 demonstrate 2 and 3 h of activation. In cells stimulated through both receptors NFAT was activated in a biphasic manner. Early that specific MAPK cascades were activated by the TCR and IL-1R. While both TCR and IL-1R activated the 'classical' enhancement of NFAT binding was detected between 15 and 60 min, followed by a second phase of enhanced NFAT-MAPK pathway, JNK and p38 MAPK were specifically activated by IL-1 in the murine T cell line EL-4 and, even more binding activity after 3-4 h of stimulation (Fig. 4A) . The connection between activation of different protein kinimportantly, in 'physiological' primary T cells.
ase cascades and transcription factors regulating the IL-2 Activation of transcription factors by TCR and IL-1R promoter was investigated by specific protein kinase inhibitors PD-98059, a specific inhibitor of MEK-1, and SB-203580, a Transcription factors represent important well-characterized targets for all three MAPK pathways activated via TCR-CD3 specific inhibitor of p38 MAPK. Preincubation with PD-98059 resulted in a partial inhibition of NFAT activation in both antior IL-1 respectively (14,25). Because IL-2 synthesis was activated synergistically by anti-CD3 and IL-1, and both stimuli CD3-and IL-1-stimulated cells (Fig. 4B) . In contrast, neither TCR-nor IL-1-stimulated NFAT activation was influenced by activated different MAPK cascades, it was obvious to study the activation of transcription factors involved in the regulation SB-203580 (data not shown). NFκB is an ubiquitous transcription factor also implied in of the IL-2 promoter. One of these, NFAT is an essential transcription factor for several cytokine genes, including IL-2 the regulation of IL-2 gene expression (reviewed in 6,26). As shown in Fig. 5(A) , stimulation of EL-4 cells by IL-1 led to a (6). To test DNA-binding activity of NFAT, oligonucleotides with the specific sequence for co-ordinate binding of NFAT rapid activation and DNA binding of NFκB, i.e. within 15 min, decreasing slowly to control levels between 30 min and 3 were used. As shown in Fig. 4(A) , both anti-CD3 antibodies and IL-1 activated DNA binding of NFAT; however, with h of activation. In contrast, upon treatment with anti-CD3 antibodies NFκB activation was detectable after 2-3 h of remarkably different kinetics. In anti-CD3-treated cells elevated NFAT binding was observed after 30 min of stimulation stimulation. In cells stimulated with the combination of anti-CD3 antibody and IL-1, activation of NFκB was continuously The specific inhibitor of MEK-1, PD-98059, proved to be an effective inhibitor of NFκB activation in anti-CD3-stimulated activated between 15 min to 3 h (Fig. 5A) . Antibodies against the p65 and p50 components competed for NFκB binding, cells (Fig. 5B) . In sharp contrast, IL-1-stimulated NFκB activation was not affected by PD-98059, suggesting that NFκB suggesting that the active factor was composed of the p50/ p65 dimer (data not shown).
activation was regulated by different molecular mechanisms
Fig. 4. TCR-CD3 complex and IL-1R activate NFAT in EL-4 cells. (A)
Activation by anti-CD3 and IL-1 of NFAT. Cells (10 7 ) were stimulated with 2.5 µg/ml anti-CD3 antibody, 2.5 ng/ml IL-1β or their combination respectively for the times indicated. Nuclear extracts were prepared and 7.5 µg of protein was incubated with 32 P-labeled oligonucleotides (20,000 c.p.m.) coding for the NFAT consensus sequence for 30 min, as described under Methods. Protein-oligonucleotide complexes were separated by PAGE (4% acrylamide) and processed to autoradiography. Results are representative for four independent experiments. (B) Influence of PD-98059 on anti-CD3-and IL-1-induced activation of NFAT. Cells (10 7 ) were preincubated with 50 µM PD-98059 for 90 min, and then stimulated with 2.5 µg/ml anti-CD3 antibody or 2.5 ng/ml IL-1β for the times indicated. Nuclear extracts were prepared and EMSA carried out as described under Methods. Results are representative for five independent experiments. via TCR and IL-1R. Neither anti-CD3-nor IL-1-stimulated MAPK by anti-CD3 (Fig. 6B) . In contrast, IL-1-induced IL-2 secretion was suppressed by both PD-98059 and SB-203580 NFκB activation was influenced by the p38 MAPK inhibitor, SB-203580 (data not shown).
by~50% of each. Combination of both inhibitors led to an 80% repression of IL-1-stimulated IL-2 secretion (Fig. 6C ).
Inhibition of different MAPK cascades results in suppression
The influence of specific protein kinase inhibitors on IL-2 of IL-2 synthesis synthesis induced by co-stimulation with anti-CD3 and IL-1 is shown in Fig. 6(D) . Both PD-98059 and SB-203580 interfered Co-stimulation of EL-4 cells with anti-CD3 and IL-1 resulted in a synergistic enhancement of IL-2 secretion (Fig. 6A) . To with IL-2 synthesis, which was reduced by Ͼ60% of each. Upon preincubation with both inhibitors IL-2 secretion was establish a link between activation of different protein kinase cascades and regulation of IL-2 synthesis, the influence of suppressed by Ͼ80%. The effects of specific protein kinase inhibitors on IL-2 specific protein kinase inhibitors on TCR-and IL-1-stimulated IL-2 synthesis has been investigated. The fact that PD-98059, specific mRNA synthesis are shown in Fig. 7 . Expression of IL-2 mRNA stimulated by anti-CD3 antibody was inhibited by a specific inhibitor of MEK-1-suppressed anti-CD3-stimulated IL-2 synthesis by 50%, while SB-203580, a specific inhibitor preincubating the cells with the specific inhibitor of MEK-1. The specific inhibitor of p38 MAPK had no influence on the of p38 MAPK, had no influence on anti-CD3-stimulated IL-2 production, is consistent with the lack of activation of p38 amount of anti-CD3-induced IL-2 mRNA. Pre-treatment of cells with both protein kinase inhibitors (PD-98059 and SB-203580) did not result in a further reduction of the amount of IL-2 specific mRNA (Fig. 7) . IL-1 also induced IL-2 mRNA synthesis; however, to a lower extent as compared to anti-CD3-stimulated cells. Preincubation with the inhibitors of MEK-1, p38 MAPK or their combinations respectively completely abolished IL-1-induced IL-2-specific mRNA production. Co-stimulation via the TCR and the IL-1R led to transcription of very high amounts of IL-2 mRNA. Both the MEK-1 and the p38 MAPK inhibitors reduced the amounts of IL-2 mRNA significantly; however, no complete inhibition of IL-2 gene transcription was observed. Preincubation of the cells with the combination of both inhibitors resulted in a further decrease in IL-2-specific mRNA level (Fig. 7) .
Correlation of the amount of IL-2 mRNA and IL-2 protein synthesis upon inhibition of distinct MAPK cascades suggests that TCR-and IL-1R-induced signals synergize at the transcriptional level to increase IL-2 gene expression. The data imply that at least two groups of MAPK, i.e. anti-CD3-and IL-1-stimulated ERK, and p38 MAPK(s) activated by IL-1, contribute to activation of the IL-2 gene transcription and synthesis. In summary, the data suggest that convergence of different MAPK cascades activated via TCR and IL-1R is necessary for maximal IL-2 synthesis in stimulated EL-4 cells. These results imply that in addition to anti-CD3, the IL-1-activated MEK/ERK signaling pathway might be of obligatory protein in different cells and cell lines. Furthermore, the JNK pathway is required for the normal regulation of AP-1 importance for IL-2 gene expression and secretion.
IL-1 effectively activates 'classical' MAPK in several nontranscriptional activity (14,32-34). These results indicate that JNK catalysed phosphorylation of its specific substrates might lymphoid cells (27) (28) (29) . Enhanced MEK catalysed ERK phosphorylation was observed upon stimulation with IL-1 in activate cytokine gene transcription also in T lymphocytes. Thus, activation of JNK might also contribute to elevation of EL-4 cells (Fig. 2A) . The fact that TCR-and IL-1-induced IL-2 synthesis was inhibited by PD-98059 to a similar extent IL-2 synthesis induced by IL-1 and anti-CD3, all the more, as a residual IL-2 secretion was observed after blocking activaindicates that IL-1-stimulated ERK activation is of equal functional importance for regulation of IL-2 gene expression.
tion of ERK and p38 MAPK (Fig. 6) . A characteristic feature of Jun (and Fos) family proteins is It should be emphasized that although both TCR and IL-1 activated the 'classical' MAPK pathway ( Fig. 2A) , ERK that they bind co-operatively with NFAT family proteins resulting in more stabile NFAT-AP-1 complexes at the NFAT phosphorylation was not further elevated upon co-stimulation with anti-CD3 and IL-1 (data not shown).
sites of the IL-2 promoter (6,35,36). As shown in Fig. 4 , both TCR and IL-1 activated DNA binding of NFAT with remarkably As depicted in Figs 2 and 3, JNK and p38 MAPK were activated to a significant extent by IL-1 both in murine differential kinetics. It remains to be elucidated whether TCR and IL-1 activated different members of the NFAT family or, thymoma cells and in splenic lymphocytes. IL-1-induced activation of both protein kinases was less prominent in alternatively, nuclear export and import, or rephosphorylation of NFAT were responsible for activation of the transcription splenic lymphocytes as compared to thymoma cells. This finding is, however, not surprising considering the significantly factor after 3-4 h in co-stimulated cells (37, 38) . In spite of this, NFAT proteins seem to be obvious targets of both TCRlower amounts of JNK and p38 MAPK proteins of splenic lymphocytes compared to thymoma cells (data not shown).
and IL-1-stimulated signaling cascades resulting in their activation, nuclear translocation and finally up-regulation of Binding of NFκB to the IL-2 promoter is required for IL-2 signaling pathway in regulation of the IL-2 gene. It should be emphasized that IL-2 synthesis and secretion induced via the gene transcription in stimulated T cells (2, 6, 26) . As shown in Fig. 5 , both TCR and IL-1 activated NFκB. However, activation TCR-CD3 complex alone were not influenced by the p38 MAPK inhibitor, ruling out non-specific effects of the subvia IL-1R resulted in fast and transient activation of NFκB, upon co-stimulation with IL-1 ϩ anti-CD3 a continuous NFκB stance, and thus also showing that IL-1-stimulated p38 MAPK and IL-2 synthesis were specifically inhibited by the subactivation was observed (Fig. 5) . Thus, stimulation via TCR and IL-1R might prolong NFκB binding to the IL-2 promoter stance. As activation of two important transcription factors, like NFAT and NFκB, regulating transactivation of the IL-2 thereby resulting in enhanced IL-2 synthesis. Although proinflammatory cytokines, e.g. IL-1, are most efficient NFκB promoter was not influenced by inhibition of p38 MAPK, the molecular mechanisms of the regulation of IL-2 gene activators (40,41), the data in Fig. 5 show that TCR-induced signaling significantly prolonged activation and nuclear bindtranscription by p38 MAPK remain to be elucidated. However, it is obvious to speculate that phosphorylation by p38 MAPK ing of NFκB. The fact that IL-1-stimulated NFκB activation was not influof well-defined molecular targets (like ATF-2 or Elk-1) or of some transcription factors not identified so far might participenced by the specific MEK inhibitor PD-98059 or the p38 MAPK inhibitor SB-203580 suggest that NFκB activation via ate in transcriptional regulation in T lymphocytes similar to several other cells (30) . Furthermore, p38 MAPK might be IL-1R represents a distinct signaling pathway independent of ERK and p38 MAPK activation. This finding is consistent with involved in the post-transcriptional regulation, i.e. in stabilization of IL-2-specific mRNA, thus contributing to elevation of recent data demonstrating that IL-1-induced activation of NFκB involves activation of a kinase complex that phosphoryl-IL-2 synthesis and secretion as shown for IL-8 specific mRNA (manuscript in preparation).
ates the IκB and is distinct of the known MAPK pathways (42,43). Activation of JNK by IL-1, as measured by enhanced phosphorylation of c-Jun, is shown in Figs 2 and 3 . It is well
In sharp contrast, anti-CD3-stimulated NFκB activation was completely inhibited upon interruption of the MEK/ERK pathdocumented that JNK family protein kinases phosphorylate the N-terminal activation domain of c-Jun resulting in activaway by PD-98059 (Fig. 5) suggesting that TCR-induced activation of NFκB obviously depends on activation and tion of the transcription factor. Besides activating c-Jun, JNK also enhance the transcriptional activity of Jun proteins functioning of the 'classical' MAPK pathway. Putative involvement of MAP (ERK) kinases in activation of IκB phosphorylation (14,30,31). Although we have no direct evidence so far for participation of IL-1-activated JNK in the regulation of IL-2 and degradation was discussed recently (44). More recent data indicated that the Cot/Tlp-2 serine-threonine kinase was synthesis, because of the lack of specific inhibitors, several reports indicated phosphorylation of c-Jun (and ATF-2), suban upstream activator of the NFκB-inducing kinase in TCR-CD28-stimulated T lymphocytes (45) . In respect to the finding sequent elevated nuclear binding, and expression of c-Jun
